Novartis | NVS - Interest Expense On Debt


Novartis reported $281M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 340M 144M Jun/2026
Bausch Health Companies USD 402M 5M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 407M 4M Jun/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
J&J USD 43M 25M Mar/2026
Merck USD 479M 67M Mar/2026
Novartis USD 462M 119M Jun/2026
Novartis USD 281M 8M Sep/2025
Pacira USD 3.7M 193K Mar/2026
Perrigo USD 7.98B 7.94B Mar/2026
Pfizer USD 667M 4M Jun/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 10.67M 636K Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Sanofi EUR -25M 99.78M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Zoetis USD 62M 5M Mar/2026